GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis, driving immunosuppression and hepatocellular carcinoma progression
Background
The molecular mechanisms linking Hepatitis B virus (HBV) infection to the progression of hepatocellular carcinoma (HCC) remain a critical knowledge gap. Current standard-of-care treatments for advanced HCC, including immunotherapies, often face challenges due to the highly immunosuppressive tumor microenvironment. Understanding how tumor cells evade immune surveillance and promote growth is crucial for developing more effective therapies. This study investigates the role of glutathione peroxidase 2 (GPX2) as a potential mediator in this complex interplay, focusing on its dual impact on tumor cell stemness and immune modulation.
Study Design
Researchers conducted single-cell analysis of HBV-positive HCC patient samples to identify distinct tumor cell populations. They characterized GPX2+ cancer stem cells (CSCs) for gene expression (MYC, CD44). In vitro experiments explored GPX2's role in mitigating ROS-mediated c-MYC distribution. In vivo studies involved models with GPX2 overexpression to assess tumorigenesis. Furthermore, they investigated the therapeutic potential of targeting CCR3 with the compound ALK4290 in combination with anti-PD-1 checkpoint blockade, evaluating its impact on tumor growth and immune sensitization.
Results
Single-cell analysis revealed a distinct population of GPX2+ CSCs within HBV-positive HCC, characterized by high MYC and CD44 expression. Intrinsically, GPX2 was found to preserve stemness by mitigating ROS-mediated c-MYC nuclear-cytoplasmic distribution. Extrinsically, GPX2 fostered immune evasion by activating the CCL26-CCR3 signaling axis. Specifically, GPX2-derived CCL26 was shown to recruit and educate B cells towards an immunosuppressive LGALS1+ state.
This LGALS1+ B cell phenotype was strongly predictive of adverse patient outcomes in HBV-driven HCC.
In vivoexperiments demonstrated that GPX2 overexpression significantly accelerated tumorigenesis. Crucially, targetingCCR3with ALK4290 effectively sensitized tumors to anti-PD-1 checkpoint blockade, indicating a reversal of the GPX2-mediated immunosuppression. These findings delineate a novel dual mechanism where GPX2 links oxidative stress regulation to immune modulation.
Key Findings
- GPX2+ cancer stem cells (CSCs) are a distinct population in HBV-positive HCC, expressing high
MYCandCD44. - GPX2 intrinsically preserves tumor stemness by mitigating ROS-mediated c-MYC nuclear-cytoplasmic distribution.
- GPX2 promotes immune evasion by activating the
CCL26-CCR3signaling axis. - GPX2-derived CCL26 recruits and educates B cells into an immunosuppressive LGALS1+ state.
- Targeting
CCR3with ALK4290 sensitizes tumors to anti-PD-1 checkpoint blockadein vivo.
Why It Matters
This research provides a critical understanding of how GPX2 drives HBV-associated HCC progression by both maintaining tumor stemness and orchestrating immune evasion. For clinicians and researchers, the identification of the GPX2-B cell axis and the CCL26-CCR3 pathway as therapeutic targets opens new avenues for HBV-driven liver cancer treatment. Targeting CCR3 with compounds like ALK4290 could enhance the efficacy of existing immunotherapies, such as anti-PD-1 checkpoint blockade, potentially improving patient outcomes. This suggests a novel combination strategy that could overcome resistance to current immunotherapies by remodeling the tumor microenvironment.
hepatocellular carcinoma
hcc
gpx2
ccl26
ccr3
lgals1